EMCDDA Home
  • EN
Search

Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available

Part (vi) New volatile inhalant outpatient clients by country and age at first use

Country<1515-1920-2425-2930-3435-3940-4445+Age knownAge not knownTotal
Belgium01000000156
Bulgaria00000000000
Czech Republic02100000303
Denmark01001000202
Germany8730000018826
Estonia5::::::::::
Ireland13210000016117
Greece10000100202
Spain11617000001341953
France1452:1::::10:
Italy200008000808
Cyprus00000000000
Latvia39200000011213
Lithuania:::::::::::
Luxembourg:::::::::::
Hungary5702000014014
Malta:::::::::::
Netherlands11000100347
Austria00000000000
Poland4:::::::::::
Portugal510000000101
Romania10100000202
Slovenia:::::::::::
Slovakia63000000909
Finland01000000101
Sweden10000000101
United Kingdom61305182221::20:
Croatia:::::::::::
Turkey:::::::::::
Norway:::::::::::
Total2111001641241112669165
 

Notes:

: Indicates no data are available

(1) Data are from 2010.

(2) In 2011 around 27% of all clients and 32% of new clients were registered as not known / missing for the primary drug category. Caution should be made when comparing data over time.

(3) In 2010 Latvia submitted a new dataset with a more precise TDI EMCDDA definition. Caution should be made when comparing data with previous years.

(4) Data are from 2010. Data presented in the table come from TDI pilot project. Caution should be made when interpreting the data.

(5) In 2010 came into implementation a new national information system implying methodological changes particularly in the registration criteria. Caution should be made when comparing 2010 data with previous years.

(6) Data are from 1st of April 2010 to 31st March 2011.

For more information relative to the treatment centre type, please see Table TDI-7.

See also Table TDI-11 part(i), part(ii)

‘General notes for interpreting data'’ on the Explanatory notes and help page.

Source:

Reitox national reports 2012- Table TDI Outpatient Treatment Centres

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Friday, 26 April 2013